Pfizer and BioNTech say they can supply 3B vaccine doses

Pfizer and BioNTech say they can supply 3B vaccine doses
© Getty Images

Pfizer and BioNTech say they can produce as many as 3 billion COVID-19 vaccine doses by the end of 2021.

In a statement to Bloomberg, BioNTech said it expected its capacity to create vaccines to exceed 3 billion by 2022. Less than six months prior to this development, the vaccine partners had said they would would be able to produce less than half this amount, indicating a sharp boost in production capability.

Bloomberg notes that this comes as demand for mRNA vaccines around the world continues to increase.


Pfizer and BioNTech had previously projected they would be able to produce around 2.5 billion doses of their vaccine this year.

This announcement also comes after Pfizer announced during an earnings call on Tuesday that its vaccine had earned it $3.5 billion in the first quarter of 2020. As of mid-April, the company said it had signed contracts accounting for 1.6 billion doses to be delivered this year.

Its first-quarter revenue totaled $14.6 billion, a 45 percent increase over what it earned in the first quarter of 2020.

Pfizer CEO Albert Bourla had said prior to the earnings call that his company expected to have the capacity to make at least 2.5 billion vaccine doses.

"Based on what we’ve seen, we believe that a durable demand for our COVID-19 vaccine — similar to that of the flu vaccines — is a likely outcome," he said.

During the call, Pfizer also shared that it planned to apply for full approval from the Food and Drug Administration by the end of May, as well as emergency use authorization for a booster shot against COVID-19 variants in July.

Pfizer currently accounts for the majority of coronavirus vaccines administered and delivered in the U.S.

According to the Centers for Disease Control and Prevention, more than 132.7 million doses of the two-dose Pfizer vaccine have been administered so far.